Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 62.00
High: 62.00
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

11 Jun 2020 13:21

RNS Number : 7070P
Tissue Regenix Group PLC
11 June 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Tissue Regenix Group Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Jupiter Asset Management Limited

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust (Custody)

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10th June 2020

6. Date on which issuer notified (DD/MM/YYYY):

11th June 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 5 %

0%

Below 5 %

7,031,597,534

Position of previous notification (if

applicable)

5.93%

N/A

5.93%

1,161,068,755

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00B5SGVL29

N/A

Below 5 %

N/A

Below 5 %

SUBTOTAL 8. A

Below 5 %

Below 5 %

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8. B 1

 

N/A

 

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

 

N/A

SUBTOTAL 8.B.2

N/A

N/A

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

Below 5 %

0%

Below 5 %

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

Contact : Jon Watson

 

Telephone Number : 0203 817 1672

 

Place of completion

London, UK

Date of completion

11th June 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAAKFFFDEEFA
Date   Source Headline
11th Mar 20163:02 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Mar 20167:00 amRNS510k market clearance granted for SurgiPureT XD
9th Mar 20167:00 amRNSFurther Medicare Coverage for DermaPure®
11th Feb 20167:00 amRNSVP, Orthopaedic, Inc. North America appointed
3rd Feb 20167:00 amRNSDermaPure to be Showcased in Nine Posters at SAWC
26th Jan 201612:21 pmRNSJoint Venture Agreement
25th Jan 20167:00 amRNSHardman & Co Research Report
20th Jan 20167:00 amRNSDermaPure® breaks through $1m sales mark
19th Jan 20167:00 amRNSAppointment of Non-Executive Director
18th Jan 20167:00 amRNSOrthoPureT XM clinical trial enrolment completed
23rd Dec 201512:40 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
4th Dec 20157:00 amRNSOrthoPureT XT implants successfully undertaken
5th Nov 20154:42 pmRNSIssue of equity and total voting rights
26th Oct 20157:00 amRNSIssue of equity and total voting rights
23rd Oct 20157:49 amRNSNon-Executive Director Share Purchase
14th Oct 20154:09 pmRNSEdison initiates coverage of Tissue Regenix
12th Oct 20157:00 amRNSInterim Results
4th Sep 201510:11 amRNSNotice of Interim Results and Capital Markets Day
30th Jul 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
22nd Jul 20157:00 amRNSAdditional US regional distribution agreement
26th Jun 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure®
12th Jun 201512:43 pmRNSResult of AGM
1st Jun 20159:17 amRNSDermaPure saves 18 year old's leg from frost bite
21st May 20159:51 amRNSHolding(s) in Company
20th May 20157:00 amRNSEmployee SAYE Share Plan
12th May 20157:00 amRNSDeferred Annual Bonus Award
11th May 20157:00 amRNSFinal Results
11th May 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
5th May 20157:02 amRNSUS regional distribution agreement signed
1st May 20154:01 pmRNSHolding(s) in Company
29th Apr 20157:01 amRNSDermaPure US Clinical data to be presented at SAWC
28th Apr 20157:00 amRNSOrthoPureT XT (Tendon) UK Clinical Trial Approval
9th Mar 20152:05 pmRNSNotice of Preliminary Results
6th Mar 20157:09 amRNSDermaPure gains Medicare coverage approval
5th Mar 20151:36 pmRNSIssue of equity and total voting rights
5th Mar 20151:18 pmRNSIssue of equity and total voting rights
5th Mar 201510:38 amRNSUK Patient has world's first OrthoPure XM implant
26th Feb 201510:43 amRNSResignation of Dr Alison Fielding
9th Feb 201512:05 pmRNSResult of General Meeting
4th Feb 201510:59 amRNSIssue of equity and total voting rights
22nd Jan 201511:13 amRNSResults of Placing
22nd Jan 20157:00 amRNSProposed placing of new Ordinary Shares
1st Dec 20149:45 amRNSHolding(s) in Company
28th Nov 20149:45 amRNSHolding(s) in Company
25th Nov 20148:15 amRNSNotice of allowance for US meniscus patent
5th Nov 20147:00 amRNSTissue Regenix gains Medicare and Medicaid Q code
29th Oct 20147:00 amRNSInterim Results
22nd Oct 20149:01 amRNSInterim Results and Capital Markets Day
20th Oct 201410:19 amRNSdCELL(R) presented at prestigious EACTS congress
17th Oct 20143:35 pmRNSInitial Clinical Trial Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.